Nikoleta Hadjigeorgiou

Ms. Nikoleta Hadjigeorgiou

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
AMAngeliki Mouzarou
Angeliki Mouzarou
NHNikoleta Hadjigeorgiou
Nikoleta Hadjigeorgiou
DMDespo Melanarkiti
Despo Melanarkiti
TPTheodora Eleni Plakomyti
Theodora Eleni Plakomyti
Hypertension is a major risk factor of various cardiac complications, including hypertensive heart disease (HHD). This condition can lead to a number of structural and functional changes in the heart, such as left ventricular hypertrophy, diastolic dysfunction, and, eventually, systolic dysfunction. In the management of hypertensive heart disease, early diagnosis and appropriate treatment are crucial for preventing the progression to congestive heart failure. One potential diagnostic marker that has gained attention in recent years is the N-terminal pro-brain natriuretic peptide (NT-proBNP). The natriuretic peptides, including the brain natriuretic peptide (BNP) and its inactive N-terminal fragment, are secreted by the myocardium in response to increased wall stress and volume overload. In patients with hypertensive heart disease, increased NT-proBNP levels may reflect the structural and functional changes occurring in the myocardium as a result of chronic pressure overload. Several studies have investigated the diagnostic utility of NT-proBNP in hypertensive heart disease. NT-proBNP levels can be a useful adjunct in the diagnosis of hypertensive heart disease, particularly in the assessment of diastolic dysfunction and left ventricular hypertrophy. This review paper explores the role of NT-proBNP levels in the diagnosis of hypertensive heart disease.

Verified
Journal Article
Open access
PDF file
Nikolaos KadoglouNikolaos Kadoglou
Nikolaos Kadoglou
AMAngeliki Mouzarou
Angeliki Mouzarou
NHNikoleta Hadjigeorgiou
Nikoleta Hadjigeorgiou
IKIOANNIS KORAKIANITIS
IOANNIS KORAKIANITIS
MMMichael Makarios Myrianthefs
Michael Makarios Myrianthefs
It has been well established that arterial hypertension is considered as a predominant risk factor for the development of cardiovascular diseases. Despite the link between arterial hypertension and cardiovascular diseases, arterial hypertension may directly affect cardiac function, leading to heart failure, mostly with preserved ejection fraction (HFpEF). There are echocardiographic findings indicating hypertensive heart disease (HHD), defined as altered cardiac morphology (left ventricular concentric hypertrophy, left atrium dilatation) and function (systolic or diastolic dysfunction) in patients with persistent arterial hypertension irrespective of the cardiac pathologies to which it contributes, such as coronary artery disease and kidney function impairment. In addition to the classical echocardiographic parameters, novel indices, like speckle tracking of the left ventricle and left atrium, 3D volume evaluation, and myocardial work in echocardiography, may provide more accurate and reproducible diagnostic and prognostic data in patients with arterial hypertension. However, their use is still underappreciated. Early detection of and prompt therapy for HHD will greatly improve the prognosis. Hence, in the present review, we shed light on the role of echocardiography in the contemporary diagnostic and prognostic approaches to HHD.

8 March 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
Nikolaos KadoglouNikolaos Kadoglou
Nikolaos Kadoglou
AMAngeliki Mouzarou
Angeliki Mouzarou
NHNikoleta Hadjigeorgiou
Nikoleta Hadjigeorgiou
IKIOANNIS KORAKIANITIS
IOANNIS KORAKIANITIS
MMMichael Makarios Myrianthefs
Michael Makarios Myrianthefs
It has been well established that hypertension is considered as a predominant risk factor for the development of cardiovascular diseases. Despite the link between hypertension and cardiovascular diseases, hypertension may directly affect the cardiac function leading in heart failure, mostly with preserved ejection fraction (HFpEF). There are echocardiographic findings indicating hypertensive heart disease (HHD) defined as altered cardiac morphology (left ventricular concentric hypertrophy, left atrium dilatation) and function (systolic or diastolic dysfunction) in patients with persistent hypertension irrespective of cardiac pathologies to which it contributes, such as coronary artery disease and kidney function impairment. In addition to classical echocardiographic parameters, novel indices, like speckle tracking of the left ventricle and left atrium, 3D volume evaluation, myocardial work in echocardiography may provide more accurate and reproducible diagnostic and prognostic data in patients with hypertension. However, their use is still underappreciated. An early detection and prompt therapy of HHD will greatly improve the prognosis. Hence, in the present review, we shed light on the role of echocardiography in the contemporary diagnostic and prognostic approach of HHD.

30 June 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
NHNikoleta Hadjigeorgiou
Nikoleta Hadjigeorgiou
DMDespo Melanarkiti
Despo Melanarkiti
TPTheodora Eleni Plakomyti
Theodora Eleni Plakomyti
VDVasileios Demou
Vasileios Demou
VGVasileios Giannakopoulos
Vasileios Giannakopoulos
AMAngeliki Mouzarou
Angeliki Mouzarou
Transcatheter aortic valve implantation (TAVI) is a minimally invasive procedure to treat severe aortic stenosis in select patients. Patients who have undergone TAVI are at high risk of infective endocarditis (IE), especially during the first year post-operation. Early diagnosis of IE is essential to initiate targeted antibiotic therapy and/or surgical intervention. However, the early detection of IE following TAVI poses significant diagnostic challenges. Current imaging techniques, including echocardiography, nuclear imaging, and magnetic resonance imaging, have varying degrees of sensitivity and specificity, each with inherent limitations. Nuclear imaging modalities, such as positron emission tomography/computed tomography using 18F-fluorodeoxyglucose (18F-FDG PET/CT) and white blood cell single photon emission computed tomography/computed tomography (WBC SPECT/CT), have shown promise in early IE detection, particularly due to the ability of these methods to identify metabolic and anatomical abnormalities. However, false-positive results related to post-operative inflammation complicate data interpretation, and limited data exist for using these methods in very early IE detection post-TAVI. Intracardiac echocardiography (ICE) offers enhanced visualization of prosthetic valve leaflets, but the invasive nature of ICE restricts its widespread use. Whole-body imaging, such as 18F-FDG PET/CT, facilitates the identification of distant lesions and systemic complications, aiding diagnosis and treatment decisions. Diagnosing IE after TAVI is especially challenging within the first 60 days post-procedure, a critical period when imaging findings may be inconclusive due to false negatives or limited availability of advanced modalities. This review underscores the diagnostic complexity of very early and early (0–60 days) IE post-TAVI, emphasizing the need for a multimodal imaging approach to overcome the limitations of individual modalities. Nonetheless, early antimicrobial therapy should be considered even without definitive imaging findings, highlighting the importance of clinical vigilance in managing this challenging condition.

12 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
AMAngeliki Mouzarou
Angeliki Mouzarou
NHNikoleta Hadjigeorgiou
Nikoleta Hadjigeorgiou
DMDespo Melanarkiti
Despo Melanarkiti
TPTheodora Eleni Plakomyti
Theodora Eleni Plakomyti
Hypertension is a major risk factor of various cardiac complications, including hypertensive heart disease. This condition can lead to a number of structural and functional changes in the heart, such as left ventricular hypertrophy, diastolic dysfunction, and eventually, systolic dysfunction. In the management of hypertensive heart disease, early diagnosis and appropriate treatment are crucial to prevent the progression to congestive heart failure. One potential diagnostic marker that has gained attention in recent years is the N-terminal pro-brain natriuretic peptide (NT-proBNP). The purpose of this paper is to explore the role of NT-proBNP levels in the diagnosis of hypertensive heart disease.

15 October 2026 in Life
Verified
Journal Article
Open access
PDF file
NHNikoleta Hadjigeorgiou
Nikoleta Hadjigeorgiou
TSTamara Stosic
Tamara Stosic
DMDespo Melanarkiti
Despo Melanarkiti
MIMaria Ioannou
Maria Ioannou
APAlexandros PAtrianakos
Alexandros PAtrianakos
AMAngeliki Mouzarou
Angeliki Mouzarou
The assessment of left and right ventricular systolic function is vital information for the management of cardiac disease. Everyday clinical practice has traditionally relied on the measurement of the ejection fraction (EF). Nonetheless, EF has known limitations and may not always accurately reflect myocardial systolic performance. Intrinsic myocardial contractility may decline long before reductions in left or right ventricular EF become apparent. Adjunct parameters such as tissue Doppler-derived systolic velocities of the mitral and tricuspid annulus may detect such early abnormalities; however, they do not represent global systolic performance. Consequently, commonly used indices may exhibit suboptimal performance for the detection of systolic dysfunction. Given the limitations of current measurement methods, there is growing concern about the reliability of heart failure (HF) classification based solely on EF. The integration of advanced echocardiographic indices, such as speckle-tracking-derived strain, three-dimensional (3D) volumetric assessment, myocardial work (MW), and cardiac power output (CPO), in combination with classical parameters provides more accurate, reproducible, and clinically meaningful diagnostic and prognostic information in patients with HF. Nevertheless, despite their potential, these techniques remain underutilized in routine practice. Early identification of systolic dysfunction and timely initiation of therapy can substantially improve clinical outcomes. In this setting, this review aims to comprehensively examine both established and emerging echocardiographic techniques used for the assessment of ventricular systolic performance, with the objective of promoting their effective integration into routine clinical practice.